This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Abraxane
  • /
  • Phase III Study of ABI-007 (Albumin-bound Paclitax...
Clinical trial

Phase III Study of ABI-007 (Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Read time: 1 mins
Last updated:1st Mar 2009

Phase III Metastatic Pancreatic Cancer

Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment: 861
Study Start Date: March 2009
Study Completion Date: April 2013
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)

- Experimental:
Albumin-bound paclitaxel (ABI-007)/Gemcitabine
- Active Comparator: Gemcitabine

Category Value
Study start date 2009-03-01

View full details